Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: February 17, 2026, 7:43 pm
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 543332 | NSE: EPIGRAL

Epigral Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: February 17, 2026, 7:43 pm

Market Cap 4,272 Cr.
Current Price 991
Intrinsic Value₹1,199.45
High / Low 2,114/903
Stock P/E12.6
Book Value 487
Dividend Yield0.61 %
ROCE24.9 %
ROE22.3 %
Face Value 10.0
PEG Ratio1.42

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Epigral Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Epigral Ltd 4,272 Cr. 991 2,114/90312.6 4870.61 %24.9 %22.3 % 10.0
Dharmaj Crop Guard Ltd 798 Cr. 236 391/16816.5 1310.00 %12.0 %9.28 % 10.0
Bhaskar Agrochemicals Ltd 65.7 Cr. 126 149/56.610.2 40.00.79 %21.3 %24.7 % 10.0
Bhagiradha Chemicals & Industries Ltd 2,718 Cr. 208 331/198112 54.90.07 %7.44 %4.91 % 1.00
Best Agrolife Ltd 650 Cr. 18.3 35.8/16.326.8 22.81.09 %12.9 %9.95 % 1.00
Industry Average10,782.75 Cr1,112.2728.56369.000.47%15.21%19.87%6.67

All Competitor Stocks of Epigral Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 538562455478472525651626645628607587597
Expenses 371407360370349369475448463454443455494
Operating Profit 16715595108123155176178183173163132103
OPM % 31%28%21%23%26%30%27%28%28%28%27%23%17%
Other Income -0521222643826
Interest 2119182120141427-012232211
Depreciation 31303132313033323334424243
Profit before tax 1141104856741131311241541311077055
Tax % 33%30%33%32%34%32%34%35%33%34%-50%26%28%
Net Profit 7777323849778681104871605239
EPS in Rs 18.5818.487.629.1811.8718.4520.7019.3824.0020.0837.1811.949.07

Last Updated: February 2, 2026, 2:46 am

Below is a detailed analysis of the quarterly data for Epigral Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

  • For Sales, as of Dec 2025, the value is 597.00 Cr.. The value appears strong and on an upward trend. It has increased from 587.00 Cr. (Sep 2025) to 597.00 Cr., marking an increase of 10.00 Cr..
  • For Expenses, as of Dec 2025, the value is 494.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 455.00 Cr. (Sep 2025) to 494.00 Cr., marking an increase of 39.00 Cr..
  • For Operating Profit, as of Dec 2025, the value is 103.00 Cr.. The value appears to be declining and may need further review. It has decreased from 132.00 Cr. (Sep 2025) to 103.00 Cr., marking a decrease of 29.00 Cr..
  • For OPM %, as of Dec 2025, the value is 17.00%. The value appears to be declining and may need further review. It has decreased from 23.00% (Sep 2025) to 17.00%, marking a decrease of 6.00%.
  • For Other Income, as of Dec 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Sep 2025) to 6.00 Cr., marking an increase of 4.00 Cr..
  • For Interest, as of Dec 2025, the value is 11.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 22.00 Cr. (Sep 2025) to 11.00 Cr., marking a decrease of 11.00 Cr..
  • For Depreciation, as of Dec 2025, the value is 43.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 42.00 Cr. (Sep 2025) to 43.00 Cr., marking an increase of 1.00 Cr..
  • For Profit before tax, as of Dec 2025, the value is 55.00 Cr.. The value appears to be declining and may need further review. It has decreased from 70.00 Cr. (Sep 2025) to 55.00 Cr., marking a decrease of 15.00 Cr..
  • For Tax %, as of Dec 2025, the value is 28.00%. The value appears to be increasing, which may not be favorable. It has increased from 26.00% (Sep 2025) to 28.00%, marking an increase of 2.00%.
  • For Net Profit, as of Dec 2025, the value is 39.00 Cr.. The value appears to be declining and may need further review. It has decreased from 52.00 Cr. (Sep 2025) to 39.00 Cr., marking a decrease of 13.00 Cr..
  • For EPS in Rs, as of Dec 2025, the value is 9.07. The value appears to be declining and may need further review. It has decreased from 11.94 (Sep 2025) to 9.07, marking a decrease of 2.87.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: December 15, 2025, 3:46 am

MetricMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 3943925987106118291,5512,1881,9292,5502,467
Expenses 2452483464054165671,0411,4991,4481,8391,815
Operating Profit 149144252306194261510689481711652
OPM % 38%37%42%43%32%32%33%31%25%28%26%
Other Income 21816224861517
Interest 191492511294466735357
Depreciation 44555554447486109124133151
Profit before tax 8875195242141161383523291540461
Tax % 23%11%20%25%21%37%34%32%33%34%
Net Profit 6767155183112101253353196357402
EPS in Rs 9.499.4021.9744.3827.1924.4860.8485.0447.1282.6893.20
Dividend Payout % 0%0%0%0%0%0%0%6%11%7%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)0.00%131.34%18.06%-38.80%-9.82%150.50%39.53%-44.48%82.14%
Change in YoY Net Profit Growth (%)0.00%131.34%-113.28%-56.86%28.98%160.32%-110.97%-84.00%126.62%

Epigral Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:33%
3 Years:18%
TTM:18%
Compounded Profit Growth
10 Years:%
5 Years:26%
3 Years:12%
TTM:72%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:7%
1 Year:-5%
Return on Equity
10 Years:%
5 Years:27%
3 Years:25%
Last Year:22%

Last Updated: September 5, 2025, 3:26 pm

Balance Sheet

Last Updated: February 1, 2026, 4:45 am

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 7171714142424242424343
Reserves 2242914472413314326841,0281,2131,8602,057
Borrowings 19012374601737753993879964593537
Other Liabilities 554279162164223405484576655598
Total Liabilities 5405276711,0441,2731,4492,1242,4322,7943,1513,235
Fixed Assets 3643983472954401,1021,0681,8041,7672,2382,176
CWIP 6937946869112658915848364309
Investments 02971000021219744
Other Assets 10698173281142221467449524752707
Total Assets 5405276711,0441,2731,4492,1242,4322,7943,1513,235

Below is a detailed analysis of the balance sheet data for Epigral Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 43.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 43.00 Cr..
  • For Reserves, as of Sep 2025, the value is 2,057.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,860.00 Cr. (Mar 2025) to 2,057.00 Cr., marking an increase of 197.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 537.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 593.00 Cr. (Mar 2025) to 537.00 Cr., marking a decrease of 56.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 598.00 Cr.. The value appears to be improving (decreasing). It has decreased from 655.00 Cr. (Mar 2025) to 598.00 Cr., marking a decrease of 57.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 3,235.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,151.00 Cr. (Mar 2025) to 3,235.00 Cr., marking an increase of 84.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 2,176.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,238.00 Cr. (Mar 2025) to 2,176.00 Cr., marking a decrease of 62.00 Cr..
  • For CWIP, as of Sep 2025, the value is 309.00 Cr.. The value appears strong and on an upward trend. It has increased from 64.00 Cr. (Mar 2025) to 309.00 Cr., marking an increase of 245.00 Cr..
  • For Investments, as of Sep 2025, the value is 44.00 Cr.. The value appears to be declining and may need further review. It has decreased from 97.00 Cr. (Mar 2025) to 44.00 Cr., marking a decrease of 53.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 707.00 Cr.. The value appears to be declining and may need further review. It has decreased from 752.00 Cr. (Mar 2025) to 707.00 Cr., marking a decrease of 45.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 3,235.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,151.00 Cr. (Mar 2025) to 3,235.00 Cr., marking an increase of 84.00 Cr..

Notably, the Reserves (2,057.00 Cr.) exceed the Borrowings (537.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +165229284626398441
Cash from Investing Activity +-363-197-455-437-401-262
Cash from Financing Activity +69-32195-200-8-164
Net Cash Flow-129124-11-1115

Free Cash Flow

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-41.0021.00178.00-295.00-543.00-492.00-483.00-190.00-483.00118.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 43414740465260283433
Inventory Days 755945586451746990105
Days Payable 31375152626942366350
Cash Conversion Cycle 86634246483492616188
Working Capital Days 434019-27-76-92-26-41-5426
ROCE %18%37%36%15%16%29%32%17%25%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters71.21%71.34%71.37%71.38%71.38%71.49%71.58%71.58%68.94%68.95%68.83%68.83%
FIIs1.15%1.20%1.16%1.14%1.17%1.36%1.46%2.10%3.01%3.01%3.06%2.71%
DIIs0.17%0.03%0.04%0.04%0.05%0.02%0.18%1.17%4.31%4.66%4.78%4.93%
Government0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%
Public27.44%27.39%27.39%27.40%27.37%27.10%26.75%25.12%23.71%23.34%23.30%23.52%
No. of Shareholders97,01694,77895,83395,74292,95988,87085,76183,17681,69780,87879,95178,605

Shareholding Pattern Chart

No. of Shareholders

Epigral Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Bandhan Small Cap Fund 690,108 0.44 84.2459,0482026-01-26 05:46:4150.33%
HSBC Value Fund 494,874 0.41 60.38N/AN/AN/A
HSBC Focused Fund 250,650 1.78 30.58N/AN/AN/A
HSBC Multi Cap Fund 237,996 0.55 29.04N/AN/AN/A
HSBC ELSS Tax saver Fund 121,645 0.36 14.84N/AN/AN/A
Bandhan Business Cycle Fund 91,662 0.77 11.18N/AN/AN/A
HSBC Flexi Cap Fund 80,365 0.19 9.81213,9652026-01-26 05:46:41-62.44%
HSBC India Export Opportunities Fund 76,533 0.66 9.34N/AN/AN/A
HSBC Business Cycles Fund 76,350 0.82 9.32N/AN/AN/A
HSBC Tax Saver Equity Fund 17,300 0.87 2.11N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 84.6847.1485.0360.8424.27
Diluted EPS (Rs.) 84.6847.1485.0360.8424.27
Cash EPS (Rs.) 113.4176.87111.2581.5141.97
Book Value[Excl.RevalReserv]/Share (Rs.) 441.48301.83257.30174.72113.88
Book Value[Incl.RevalReserv]/Share (Rs.) 441.48301.83257.30174.72113.88
Revenue From Operations / Share (Rs.) 591.13464.30526.69373.27199.41
PBDIT / Share (Rs.) 168.27117.39167.73123.6163.42
PBIT / Share (Rs.) 137.5487.66141.51102.9345.72
PBT / Share (Rs.) 125.2069.97125.7592.2838.71
Net Profit / Share (Rs.) 82.6847.1385.0360.8424.27
NP After MI And SOA / Share (Rs.) 82.9147.1485.0360.8424.27
PBDIT Margin (%) 28.4625.2831.8433.1131.80
PBIT Margin (%) 23.2618.8726.8627.5722.92
PBT Margin (%) 21.1715.0623.8724.7219.41
Net Profit Margin (%) 13.9810.1516.1416.2912.16
NP After MI And SOA Margin (%) 14.0210.1516.1416.2912.16
Return on Networth / Equity (%) 18.7815.6133.0434.8221.30
Return on Capital Employeed (%) 22.3018.0732.9426.8717.92
Return On Assets (%) 11.347.0014.5211.906.96
Long Term Debt / Equity (X) 0.230.390.401.060.71
Total Debt / Equity (X) 0.300.720.711.360.87
Asset Turnover Ratio (%) 0.850.730.960.860.00
Current Ratio (X) 1.570.640.640.830.46
Quick Ratio (X) 0.780.300.320.550.32
Inventory Turnover Ratio (X) 7.834.516.627.300.00
Dividend Payout Ratio (NP) (%) 8.825.302.940.000.00
Dividend Payout Ratio (CP) (%) 6.433.252.240.000.00
Earning Retention Ratio (%) 91.1894.7097.060.000.00
Cash Earning Retention Ratio (%) 93.5796.7597.760.000.00
Interest Coverage Ratio (X) 13.636.6410.6411.609.05
Interest Coverage Ratio (Post Tax) (X) 7.703.666.396.714.46
Enterprise Value (Cr.) 8753.815509.594780.475010.230.00
EV / Net Operating Revenue (X) 3.432.862.183.230.00
EV / EBITDA (X) 12.0611.306.869.760.00
MarketCap / Net Operating Revenue (X) 3.212.361.792.610.00
Retention Ratios (%) 91.1794.6997.050.000.00
Price / BV (X) 4.303.633.675.570.00
Price / Net Operating Revenue (X) 3.212.361.792.610.00
EarningsYield 0.040.040.090.060.00

After reviewing the key financial ratios for Epigral Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 84.68. This value is within the healthy range. It has increased from 47.14 (Mar 24) to 84.68, marking an increase of 37.54.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 84.68. This value is within the healthy range. It has increased from 47.14 (Mar 24) to 84.68, marking an increase of 37.54.
  • For Cash EPS (Rs.), as of Mar 25, the value is 113.41. This value is within the healthy range. It has increased from 76.87 (Mar 24) to 113.41, marking an increase of 36.54.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 441.48. It has increased from 301.83 (Mar 24) to 441.48, marking an increase of 139.65.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 441.48. It has increased from 301.83 (Mar 24) to 441.48, marking an increase of 139.65.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 591.13. It has increased from 464.30 (Mar 24) to 591.13, marking an increase of 126.83.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 168.27. This value is within the healthy range. It has increased from 117.39 (Mar 24) to 168.27, marking an increase of 50.88.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 137.54. This value is within the healthy range. It has increased from 87.66 (Mar 24) to 137.54, marking an increase of 49.88.
  • For PBT / Share (Rs.), as of Mar 25, the value is 125.20. This value is within the healthy range. It has increased from 69.97 (Mar 24) to 125.20, marking an increase of 55.23.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 82.68. This value is within the healthy range. It has increased from 47.13 (Mar 24) to 82.68, marking an increase of 35.55.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 82.91. This value is within the healthy range. It has increased from 47.14 (Mar 24) to 82.91, marking an increase of 35.77.
  • For PBDIT Margin (%), as of Mar 25, the value is 28.46. This value is within the healthy range. It has increased from 25.28 (Mar 24) to 28.46, marking an increase of 3.18.
  • For PBIT Margin (%), as of Mar 25, the value is 23.26. This value exceeds the healthy maximum of 20. It has increased from 18.87 (Mar 24) to 23.26, marking an increase of 4.39.
  • For PBT Margin (%), as of Mar 25, the value is 21.17. This value is within the healthy range. It has increased from 15.06 (Mar 24) to 21.17, marking an increase of 6.11.
  • For Net Profit Margin (%), as of Mar 25, the value is 13.98. This value exceeds the healthy maximum of 10. It has increased from 10.15 (Mar 24) to 13.98, marking an increase of 3.83.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 14.02. This value is within the healthy range. It has increased from 10.15 (Mar 24) to 14.02, marking an increase of 3.87.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 18.78. This value is within the healthy range. It has increased from 15.61 (Mar 24) to 18.78, marking an increase of 3.17.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 22.30. This value is within the healthy range. It has increased from 18.07 (Mar 24) to 22.30, marking an increase of 4.23.
  • For Return On Assets (%), as of Mar 25, the value is 11.34. This value is within the healthy range. It has increased from 7.00 (Mar 24) to 11.34, marking an increase of 4.34.
  • For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has decreased from 0.39 (Mar 24) to 0.23, marking a decrease of 0.16.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.72 (Mar 24) to 0.30, marking a decrease of 0.42.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 0.85. It has increased from 0.73 (Mar 24) to 0.85, marking an increase of 0.12.
  • For Current Ratio (X), as of Mar 25, the value is 1.57. This value is within the healthy range. It has increased from 0.64 (Mar 24) to 1.57, marking an increase of 0.93.
  • For Quick Ratio (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has increased from 0.30 (Mar 24) to 0.78, marking an increase of 0.48.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.83. This value is within the healthy range. It has increased from 4.51 (Mar 24) to 7.83, marking an increase of 3.32.
  • For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 8.82. This value is below the healthy minimum of 20. It has increased from 5.30 (Mar 24) to 8.82, marking an increase of 3.52.
  • For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.43. This value is below the healthy minimum of 20. It has increased from 3.25 (Mar 24) to 6.43, marking an increase of 3.18.
  • For Earning Retention Ratio (%), as of Mar 25, the value is 91.18. This value exceeds the healthy maximum of 70. It has decreased from 94.70 (Mar 24) to 91.18, marking a decrease of 3.52.
  • For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.57. This value exceeds the healthy maximum of 70. It has decreased from 96.75 (Mar 24) to 93.57, marking a decrease of 3.18.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 13.63. This value is within the healthy range. It has increased from 6.64 (Mar 24) to 13.63, marking an increase of 6.99.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.70. This value is within the healthy range. It has increased from 3.66 (Mar 24) to 7.70, marking an increase of 4.04.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 8,753.81. It has increased from 5,509.59 (Mar 24) to 8,753.81, marking an increase of 3,244.22.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has increased from 2.86 (Mar 24) to 3.43, marking an increase of 0.57.
  • For EV / EBITDA (X), as of Mar 25, the value is 12.06. This value is within the healthy range. It has increased from 11.30 (Mar 24) to 12.06, marking an increase of 0.76.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.36 (Mar 24) to 3.21, marking an increase of 0.85.
  • For Retention Ratios (%), as of Mar 25, the value is 91.17. This value exceeds the healthy maximum of 70. It has decreased from 94.69 (Mar 24) to 91.17, marking a decrease of 3.52.
  • For Price / BV (X), as of Mar 25, the value is 4.30. This value exceeds the healthy maximum of 3. It has increased from 3.63 (Mar 24) to 4.30, marking an increase of 0.67.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.36 (Mar 24) to 3.21, marking an increase of 0.85.
  • For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Epigral Ltd as of February 18, 2026 is: ₹1,101.38

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 18, 2026, Epigral Ltd is Undervalued by 11.14% compared to the current share price ₹991.00

Intrinsic Value of Epigral Ltd as of February 18, 2026 is: ₹1,199.45

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 18, 2026, Epigral Ltd is Undervalued by 21.03% compared to the current share price ₹991.00

Last 5 Year EPS CAGR: 8.90%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 22.50%, which is a positive sign.
  2. The stock has a low average Working Capital Days of -18.80, which is a positive sign.
  3. The company has higher reserves (800.73 cr) compared to borrowings (585.82 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (322.00 cr) and profit (281.82 cr) over the years.
  1. The stock has a high average Cash Conversion Cycle of 62.10, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Epigral Ltd:
    1. Net Profit Margin: 13.98%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 22.3% (Industry Average ROCE: 15.21%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 18.78% (Industry Average ROE: 19.87%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 7.7
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.78
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 12.6 (Industry average Stock P/E: 28.56)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.3
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Epigral Ltd. is a Public Limited Listed company incorporated on 11/09/2007 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24100GJ2007PLC051717 and registration number is 051717. Currently Company is involved in the business activities of Manufacture of organic and inorganic chemical compounds. Company's Total Operating Revenue is Rs. 2550.13 Cr. and Equity Capital is Rs. 43.14 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Agro Chemicals/Pesticides�Epigral Tower�, Behind Safal Profitaire, Ahmedabad Gujarat 380015Contact not found
Management
NamePosition Held
Mr. Maulik PatelChairman & Managing Director
Mr. Kaushal SoparkarExecutive Director
Mr. Ankit PatelNon Exe.Non Ind.Director
Mr. Karana PatelNon Exe.Non Ind.Director
Mr. Darshan PatelNon Exe.Non Ind.Director
Mr. Manubhai PatelIndependent Director
Mr. Sanjay AsherIndependent Director
Mr. Kanubhai PatelIndependent Director
Mr. Raju SwamyIndependent Director
Ms. Priyanka ChopraIndependent Woman Director

FAQ

What is the intrinsic value of Epigral Ltd?

Epigral Ltd's intrinsic value (as of 17 February 2026) is ₹1199.45 which is 21.03% higher the current market price of ₹991.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹4,272 Cr. market cap, FY2025-2026 high/low of ₹2,114/903, reserves of ₹2,057 Cr, and liabilities of ₹3,235 Cr.

What is the Market Cap of Epigral Ltd?

The Market Cap of Epigral Ltd is 4,272 Cr..

What is the current Stock Price of Epigral Ltd as on 17 February 2026?

The current stock price of Epigral Ltd as on 17 February 2026 is ₹991.

What is the High / Low of Epigral Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Epigral Ltd stocks is ₹2,114/903.

What is the Stock P/E of Epigral Ltd?

The Stock P/E of Epigral Ltd is 12.6.

What is the Book Value of Epigral Ltd?

The Book Value of Epigral Ltd is 487.

What is the Dividend Yield of Epigral Ltd?

The Dividend Yield of Epigral Ltd is 0.61 %.

What is the ROCE of Epigral Ltd?

The ROCE of Epigral Ltd is 24.9 %.

What is the ROE of Epigral Ltd?

The ROE of Epigral Ltd is 22.3 %.

What is the Face Value of Epigral Ltd?

The Face Value of Epigral Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Epigral Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports